An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia

Trial Profile

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 29 Jun 2016 This trial was completed in Finland, Bulgaria, Slovakia and Spain according to the European Clinical Trials Database.
    • 14 Aug 2013 Planned number of patients changed from 550 to 708 as reported by ClinicalTrials.gov.
    • 14 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top